Background {#Sec1}
==========

Renal cell carcinoma (RCC) is the most frequently diagnosed renal malignancy \[[@CR1]\]. Owing to the constant advances of modern imaging technologies, the percentage of incidentally detected renal tumours has constantly increased during the last couple of decades \[[@CR2], [@CR3]\]. Although those phenomena brought the overall stage downward migration, a good percentage of patients are still diagnosed with metastatic renal cell carcinoma (mRCC) \[[@CR3]\]. The use of cytoreductive nephrectomy in these patients with mRCC was reported to have significant survival benefits in several studies \[[@CR4]\]. Therefore, further understanding of prognostic biomarkers is becoming more clinically important in selecting adequate candidates for adjuvant or neoadjuvant therapies for patients with mRCC perioperatively.

Several studies have reported a significant inverse relationship between obesity and RCC prognosis \[[@CR5]--[@CR7]\]. Although obesity is a well-known risk factor for the development of RCC \[[@CR7]\], most studies reported that obese patients show more favourable pathology and survival outcomes, a phenomenon known as the "obesity paradox" \[[@CR5], [@CR6]\]. A large multicentre study recently analysed a large multi-institutional database of patients with mRCC and showed that patients with a low body mass index (BMI) showed significant worse survival compared to those with a high BMI \[[@CR6]\]. They also showed that the high fatty acid synthase (FAS) expression was observed in patients with low BMI was connected to the worse survival outcomes. Their results suggest that the lipid metabolism is one of the important tumour metabolic mechanisms that are essential to tumour survival and progression. Since cholesterol is an essential cellular component that plays a crucial role in lipid metabolism, preoperative serum cholesterol level (PCL) may have significant correlation with prognosis in RCC patients \[[@CR8]\]. Unfortunately, only two studies investigated this subject, both of which included small samples of patients with localized RCC but none with mRCC. Therefore, here we aimed to investigate the possible associations of PLC with survival outcomes in patients with mRCC after cytoreductive nephrectomy.

Methods {#Sec2}
=======

We retrospectively analysed the data of 281 patients diagnosed with mRCC and initially treated with nephrectomy at multiple centres of South Korea. The informed consent has been waived by an approval of our institutional ethical review boards due to retrospective design (IRB number: B-1702/384--102). After the exclusion of 37 patients (neoadjuvant therapy \[*n* = 7\], other malignancy \[*n* = 13\], incomplete information \[*n* = 17\]), we finally included 244 patients. The clinical and pathological information was retrieved from prospectively managed databases of each institution. Every patient was initially evaluated using chest computed tomography (CT) (or simple radiography), abdominal CT, and bone scan. The PCL was included in the routine chemistry panels which was performed as a part of preoperative anesthetic risk evaluation within 4 weeks preceding the surgery. If there were multiple measurements before the surgical treatment, mean values were regarded as representative.

Pathological stage and histological subtype were determined according to the seventh TNM classification from the American Joint Committee Cancer Guidelines and the Heidelberg recommendations \[[@CR9], [@CR10]\]. The nuclear grades of the tumour cells were evaluated according to Fuhrman's grading system \[[@CR11]\]. The survival data and cause of death were determined by a rigorous review of the Korean National Statistical Office's database and medical records of each hospital. The follow-up protocols varied slightly among institutions or physicians but usually included 3 month intervals after surgery. The receiver operating curve of PCL on the cancer-specific mortality was analysed and the area under the curve was 0.598. Since a PCL of 170 mg/dL showed the maximal Youden index value, the cut-off value was set at 170 mg/dL (Fig. [1](#Fig1){ref-type="fig"}). Therefore, the subjects with values ≥170 mg/dL were regarded the high PCL group and the others (PCL \< 170 mg/dL) were regarded the low PCL group.Fig. 1The receiver operating curve of preoperative cholesterol level upon cancer-specific mortality (*Vertical black line* indicates the points with maximal Youden's value)

Independent T and chi-square tests were performed to compare the clinicopathological characteristics of the high and low PCL groups. To compare the survival outcomes of the two subgroups, Kaplan--Meier analyses were performed. Using multivariate Cox-proportional hazard models, the possible predictors of overall survival (OS), and cancer-specific survival (CSS) were tested. All of the statistical analyses were performed using SPSS software (version 19.0; SPSS, Chicago, IL, USA). All of the *p* values were two-sided and those \<0.05 were considered statistically significant.

Results {#Sec3}
=======

The clinical and pathological profiles of the entire cohort and subgroups according to the PCL are summarized in Table [1](#Tab1){ref-type="table"}. The median age was 59.0 years (interquartile range \[IQR\], 52.0--68.0); median tumour diameter was 8.0 cm (IQR, 5.6--10.5), median PCL was 156.0 (IQR, 132.3--173.8), and median follow-up time was 13.0 months (IQR, 6.0--26.5). There were 88 patients in the high PCL group and 156 patients in the low PCL group. The low PCL group showed significantly lower haemoglobin level (*p* \< 0.001) and higher platelet level (*p* = 0.038) than the high PCL group, but no significant differences were noted in the other clinical characteristics or pathological outcomes between the two groups.Table 1Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol level of 170 mg/dL cut-offEntire patients (*n* = 244)High PCL group (*n* = 72)Low PCL group (*n* = 172)*p* valueMedian (IQR) or Number (percent)Age (y)59.0 (52.0--68.0)57.5 (52.0--67.0)60.0 (51.3--68.8)0.981BMI (*kg*/*m* ^2^)23.0 (21.0--24.8)23.5 (21.8--42.8)22.9 (20.8--24.9)0.239Sex (male)185 (75.8%)50 (69.4%)135 (78.5%)0.091Serum Albumin (g/dL)4.0 (3.5--4.3)4.3 (3.9--4.4)3.9 (3.4--4.2)\< 0.001Hemoglobin (g/dL)12.1 (10.6--13.6)13.1 (11.7--14.7)11.8 (10.3--13.1)\< 0.001Platelet (k/dL)274.5 (132.3--173.8)271.5 (212.5--320.5)299.8 (222.0--378.8)0.038PLC (mg/dL)156.0 (132.3--173.8)190 (178--205.8)139.1 (126.3--157.8)Corrected calcium (mg/dL)9.2 (8.9--9.7)9.4 (9.0--9.8)9.5 (8.8--9.6)ECOG score (≥2)79 (32.4%)22 (30.6%)57 (33.1%)0.765Diabetes mellitus60 (24.7%)14 (19.7%)46 (26.7%)0.326Hypertension120 (49.6%)33 (46.5%)87 (50.9%)0.574Tumor size (cm)8.0 (5.6--10.5)6.5 (5.0--9.5)8.7 (6.1--11.0)0.407Clinical stage (≥3)138 (56.6%)32 (44.4%)106 (61.6%)0.059Metastatic sites0.541 Lung78 (32.0%)23 (31.9%)55 (32.0%) Liver7 (2.7%)1 (1.4%)5 (2.9%) Bone24 (9.8%)10 (13.9%)14 (8.1%) Non-regional LNI2 (1.0%)0 (0%)2 (1.2%) Adrenal gland8 (3.3%)4 (5.6%)4 (2.3%) Multiple metastasis10 (4.1%)3 (4.2%)7 (4.1%) Information missing108 (44.3%)33 (45.8%)75 (43.6%) Miscellaneous2 (1.0%)0 (0%)2 (1.2%)Pathologic stage0.060 pT160 (24.6%)24 (33.3%)36 (20.9%) pT236 (14.8%)11 (15.3%)25 (14.5%) pT3117 (48.0%)33 (45.8%)84 (48.8%) pT431 (12.7%)4 (5.6%)27 (15.7%)Fuhrman grade0.424  ≤ 234 (13.9%)12 (16.7%)22 (12.8%)  ≥ 3210 (86.1%)60 (83.3%)150 (87.2%)Histologic subtype0.214 Clear cell213 (87.3%)67 (93.1%)146 (84.9%) Papillary13 (5.3%)2 (2.8%)11 (6.4%) Chromophobe4 (1.6%)0 (0%)4 (2.3%) Collecting duct5 (2.0%)1 (1.4%)4 (2.3%) Unclassified9 (3.7%)2 (2.8%)7 (4.1%)*IQR* interquartile range, *PCL* preoperative cholesterol level, *BMI* body mass index, *ECOG* Eastern Cooperative Oncology Group, *LNI* lymph node invasion

After a median follow-up of 12.0 months (IQR, 7.0--23.0), 85 patients died because of RCC. A total of 101 all-cause mortalities occurred after a median follow-up of 13.0 months (IQR, 7.0--23.5). The low PCL group showed significantly worse CSS (*p* = 0.013) and OS (*p* = 0.009) than the high PCL group (Fig. [2](#Fig2){ref-type="fig"}). The results from univariate Cox proportional analyses on CSS and OS were summarized in Table [2](#Tab2){ref-type="table"}. Multivariate Cox proportional analysis revealed that low PCL was the independent predictor for worse CSS (HR, 2.162; 95% CI, 1.221--3.829; *p* = 0.008) and OS (HR, 2.013; 95% CI, 1.206--3.361; *p* = 0.007) (Table [3](#Tab3){ref-type="table"}). When we stratified the patients by tumour histology (clear cell versus non-clear cell types), low PCL was revealed as an independent predictor for worse CSS (HR, 2.312; 95% CI, 1.274--4.193; *p* = 0.006) and OS (HR, 2.204; 95% CI, 1.279--3.799; *p* = 0.004) in the clear cell subgroup (Table [4](#Tab4){ref-type="table"}). However, there were no significant relationships between PCL and survival outcomes in the non-clear cell subgroup (all *p* values \>0.05). Subsequently, we further stratified the entire patient cohort into three risk groups (favourable, intermediate, poor) according to Heng's model. We observed worse survival outcomes in the low PCL group, but the results did not reach statistical significance due to the small number of subjects (Table [4](#Tab4){ref-type="table"}).Fig. 2Kaplan-Meier analyses of cancer-specific survival (**a**) and overall survival (**b**) by preoperative cholesterol level Table 2Univariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244 patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinomaCancer-specific survivalOverall survivalHR95% CI of HR*p* valueHR95% CI of HR*p* valueAge1.0040.986--1.0230.6791.0050.989--1.0230.530BMI (*kg*/*m* ^2^)Reference (\< 20)Reference (\< 20) 20--250.7780.456--1.3270.3560.7830.478--1.2830.332  ≥ 250.3730.182--0.7620.0070.3870.202--0.7430.004Albumin (g/dL)Reference (\< 3.5)Reference (\< 3.5) 3.5--4.30.6100.375--0.9910.0460.5770.371--0.8990.015  ≥ 4.30.5150.290--0.9160.0240.4850.286--0.8220.007Heng's criteriaReference (Low risk)Reference (Low risk) Intermediate risk1.2650.729--2.1980.4031.1880.720--1.9610.499 High risk1.8420.957--3.5460.0671.8060.999--3.2660.050 Cholesterol level (cat.)2.2511.285--3.9410.0052.1001.272--3.4660.004*HR* hazard ratio, *CI* confidence interval, *BMI* body mass index, *cat.* Categorical variable Table 3Multivariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244 patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinomaCancer-specific survivalOverall survivalHR95% CI of HR*p* valueHR95% CI of HR*p* valueAge1.0020.983--1.0210.8651.0030.986--1.0210.713BMI (*kg*/*m* ^2^)Reference (\< 20)Reference (\< 20) 20--250.7920.459--1.3690.4040.8050.485--1.3360.402  ≥ 250.4430.202--0.9240.0300.4660.232--0.9360.032Albumin (g/dL)Reference (\< 3.5)Reference (\< 3.5) 3.5--4.30.7760.440--1.3700.3820.7160.426--1.2040.208  ≥ 4.30.7840.399--1.5440.4820.7130.383--1.3280.287Heng's criteriaReference (Low risk)Reference (Low risk) Intermediate risk1.0950.623--1.9260.7521.0330.619--1.7250.902 High risk1.1850.550--2.5530.6641.1320.565--2.2700.727 Cholesterol level (cat.)2.1621.221--3.8290.0082.0131.206--3.3610.007Age1.0020.983--1.0210.8301.0030.986--1.0210.701BMI (*kg*/*m* ^2^)Reference (\< 20)Reference (\< 20) 20--250.8270.479--1.4300.4970.8570.517--1.4200.549  ≥ 250.4620.214--0.9970.0490.5030.249--1.0170.056Albumin (g/dL)Reference (\< 3.5)Reference (\< 3.5) 3.5--4.30.8820.498--1.5610.6650.7890.468--1.3270.371  ≥ 4.30.8920.437--1.8210.7530.7690.401--1.4730.428Heng's criteriaReference (Low risk)Reference (Low risk) Intermediate1.0600.601--1.8700.8401.0240.613--1.7120.927 High risk1.2350.576--2.6490.5881.1930.596--2.3890.618 Cholesterol level (con.)0.9930.987--0.9990.0320.9950.989--1.0000.063*HR* hazard ratio, *CI* confidence interval, *BMI* body mass index, *con.* Continuous variable, *cat.* Categorical variable Table 4Multivariate Cox hazard ratio models for the impact of low cholesterol on cancer-specific and overall survival after surgical treatment of metastatic renal cell carcinomaCancer-specific survivalOverall survivalHR95% CI of HR*p*-valueHR95% CI of HR*p*-valueEntire cohorts2.1621.221--3.8290.0082.0131.206--3.3610.007Subgroups according to the tumor histology Clear cell histology2.3121.274--4.1930.0062.2041.279--3.7990.004 Other histology0.7670.076--7.7710.8220.2850.043--1.8790.192Subgroups according to the Heng's model Favorable risk1.5560.487--4.9670.4551.7670.602--5.1850.300 Intermediate1.8090.907--3.6110.0931.5830.851--2.9470.147 Poor1.5380.339--6.9720.5771.7350.406--7.4160.457Multivariate analyses were adjusted for age, body mass index, Heng's risk group, preoperative albumin and cholesterol level. *HR* hazard ratio, *CI* confidence interval

Discussion {#Sec4}
==========

In the present study, we found that low PCL was independently correlated with worse survival outcomes in mRCC patients treated by cytoreductive nephrectomy. Interestingly, PCL showed significant results in the clear cell type RCC but not in the non-clear cell RCC, which implies that lipid metabolism is mainly associated with clear cell subtype RCC. The PCL showed high HR in all three risk groups according to Heng's criteria, although the results were non-significant due to the small number of included subjects.

Malignant cells have the notable feature of invasiveness and relentless proliferation, both of which require profound energy and raw materials. To support those abilities, most cancer cells have special metabolisms that enable them to promote their survival. This phenomenon has been termed "metabolic transformation" \[[@CR12]\]. Among those, the most well-known metabolism in cancer cells is the "Warburg effect" \[[@CR13]\]. Warburg et al. found that cancer cells produced adenosine triphosphate by non-aerobic glycolysis even in circumstances of sufficient oxygen, and this peculiar metabolism is beneficial because it produces less reactive oxygen species, which are hazardous to cancer cells due to the oxidative stress. Along with glucose metabolism, lipid metabolism is crucial to maintaining cancer proliferation and finishing the new building blocks because proliferating cells require plenty of nucleotides, fatty acids, membrane lipids, and proteins. Many cancer cells show high rates of de novo lipid synthesis \[[@CR14]\].

Since cholesterol is an essential component of cellular membranes and important in energy production of tumour survival, the several previous studies investigated the relationship between cholesterol level and cancer development \[[@CR15]--[@CR17]\]. A large epidemiologic study analysed 33,368 Japanese subjects and concluded the presence of an increased incidence of stomach and liver cancers in patients having low cholesterol levels \[[@CR15]\]. Another prospective study by Asano et al. also demonstrated that there were inverse association between cholesterol level and gastric cancer incidence after analysing the data of 2604 subjects for 14 years follow-up \[[@CR16]\]. Kitahara et al. recently performed a retrospective analysis of a large database from South Korea with 1 million subjects and concluded that cholesterol level was correlated with increased incidence of several malignancies \[[@CR17]\]. However, the influence of cholesterol was quite heterogeneous between the different malignancies. From their results, prostate, colon, and breast cancer showed high incidences in patients with high cholesterol, whereas liver, stomach, and lung cancer showed high incidences in patients with low cholesterol, showing that the relationship is quite variable and cancer-specific. Apart from the increased incidences, little has been investigated about the relationship between cholesterol level and cancer prognosis. Ohno et al. analysed 364 clear cell RCC patients and reported that a high PCL was associated with better CSS, although the findings of their multivariate analysis were not statistically significant due to a small number of subjects \[[@CR18]\]. Another study by Martino et al. analysed a larger cohort of 867 subjects with localized RCC and concluded that low PCL independently correlated with worse CSS \[[@CR19]\]. To our best knowledge, our study is the first to evaluate the prognostic value of PCL in patients with mRCC.

As the terminology "clear cell" indicates, the clear cell type of RCC accumulates significant amounts of cholesterol ester and glycogen in the cytosol \[[@CR20]\]. Furthermore, several genes involved in lipid metabolism were previously reported to be related with clear cell type RCC progression \[[@CR21]\]. In the present study, PCL showed significant associations in clear cell subtypes but not in non-clear cell subtypes, which implicates these relationship is intact only in the clear cell subtype. However, the exact mechanism or pathways underneath these phenomena are obscure and require elucidation.

Our study has several important limitations. First, the retrospective design and information gathering method are not immune to recall bias. Second, we could not analyse the influence of specific drugs such as statins. Third, patients received different salvage or palliative therapies from different attending physicians. Finally, we included only mRCC patients treated with nephrectomy, and further studies are needed to confirm our findings in all patients with mRCC.

Conclusion {#Sec5}
==========

Preoperative serum cholesterol level was associated with worse survival outcomes in patients with mRCC after treatment with cytoreductive nephrectomy. Further basic studies are needed to elucidate the exact lipid metabolism underlying this peculiar phenomenon.
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